A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Summary

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

Timeline

Start

2024-07-19

Primary completion

2026-07-31

Completion

2028-07-31

Drugs

Indications